Dr. Pavel Hamet, MD, PhD
Claim this profileClinical Trials Pavel Hamet, MD, PhD is currently running
More about Pavel Hamet, MD, PhD
Clinical Trial Related
1 year of experience running clinical trials · Led 1 trial as a Principal Investigator · 1 Active Clinical Trial
Treatments Pavel Hamet, MD, PhD has experience with
- Polygenic Risk Score
Breakdown of trials Pavel Hamet, MD, PhD has run
Genetic Risk Score
Cardiovascular Disease
Diabetic Kidney Disease
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Pavel Hamet, MD, PhD specialize in?
Pavel Hamet, MD, PhD focuses on Type 2 Diabetes and Genetic Risk Score. In particular, much of their work with Type 2 Diabetes has involved treating patients, or patients who are undergoing treatment.
Is Pavel Hamet, MD, PhD currently recruiting for clinical trials?
Yes, Pavel Hamet, MD, PhD is currently recruiting for 1 clinical trial in the USA. If you're interested in participating, you should apply.
Are there any treatments that Pavel Hamet, MD, PhD has studied deeply?
Yes, Pavel Hamet, MD, PhD has studied treatments such as Polygenic Risk Score.
What is the best way to schedule an appointment with Pavel Hamet, MD, PhD?
Apply for one of the trials that Pavel Hamet, MD, PhD is conducting.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.